Navigation Links
Cephalon Files Definitive Consent Revocation Statement, Commences Mailing to Shareholders
Date:4/21/2011

sing a short deadline of May 12th which is in advance of the timeline provided by Delaware law, reinforcing our view that Valeant's self-serving agenda is to prevent shareholders from having time to maximize value for their shares.

All these observations drive to one simple conclusion – Valeant's non-binding proposal is nothing but an opportunistic attempt by Valeant to shift the value of Cephalon's products and pipeline to Valeant and its shareholders at the expense of Cephalon shareholders.(1)  Life science acquisitions since 2006 of greater than $500 million with greater than 50% cash consideration.(2)  Valeant Offer for Cephalon Still Lowest Drug Deal With 15% Boost: Real M&A, Bloomberg, March 31, 2011.(3)  Includes one product that has completed Phase 3 development, four in Phase 3 development, three that have completed Phase 2 development and two in Phase 2b development.VALEANT HAS NO DUTY TO ACT IN YOUR BEST INTERESTS -- VALEANT'S NOMINEES WERE HAND-PICKED TO SELL CEPHALON TO VALEANTValeant has no duty whatsoever to act in your best interests or to provide you with full and fair value for your shares.  Valeant acts for its shareholders and their interests – such as buying Cephalon at the lowest possible price and by picking board nominees who will facilitate such a sale at the lowest price possible.  

Although Valeant has described its slate of nominees as "independent" and subject to fiduciary duties if elected, Cephalon's Board of Directors believes that Valeant's nominees have been selected by Valeant simply to facilitate the acquisition of Cephalon by Valeant on terms that are as favorable to Valeant and its shareholders as possible.  In fact, Valeant has stated its expectation that its nominees, if elected, will facilitate its $73 per share non-binding proposal.

Valeant has not indicated whether its nominees intend to seek and consider superior alternatives to Valeant's p
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Cephalon Quarterly Conference Call Invitation
2. Cephalon Concludes All Outstanding Federal and State Government Investigations into the Companys Sales and Promotional Practices
3. $425 Million Cephalon Civil Settlement and Criminal Fine; In Americas Largest
4. Cephalon Launches National Consumer Awareness Initiative on Appropriate Use of Prescription Opioid Medications
5. Cephalon and Eurand Announce Notification of Generic Filing for Cyclobenzaprine Hydrochloride Extended-Release Capsules
6. Cephalon Reports Another Strong Quarter
7. Cephalon, Inc. to Webcast Analyst Day
8. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
9. Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor
10. Cephalon Appoints Sarma P. Duddu as General Manager and Vice President of Drug Delivery Technologies for CIMA LABS
11. Cephalons New Product Launches Pace Record 2008 Sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Jose, California (PRWEB) September 19, 2014 ... Nanotechnology and its potential to revolutionize the world ... agencies, multinational corporations and small start-ups. The early ... funded research projects largely due to the high ... investments. Government budgets earmarked for this evolving technology ...
(Date:9/19/2014)... , Sept. 19, 2014 Pfenex Inc. ... the development of high-value and difficult to manufacture proteins ... presenting at the 21 st Annual NewsMakers in ... . Bertrand Liang , chief executive officer ... development programs and business strategy on Friday, September 26, ...
(Date:9/19/2014)... 19, 2014 ... ) has announced the addition of the  "Micro ... to their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... of the fastest-growing segments in the chromatography market. ... 2013, and expected to reach $2.0 billion by ...
(Date:9/18/2014)... September 18, 2014 HealthTronics, ... and interventional radiology products and services, announced that ... cryotherapy and cryoablation) versus external beam radiotherapy (EBRT) ... the American Urological Association (MAAUA) Annual Meeting in ... Relative Effectiveness of Cryosurgery and External Beam Radiation ...
Breaking Biology Technology:Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 4Pfenex to Present at Upcoming Industry Conference on September 26 2Micro Market Monitor : Global Pre-packed Chromatography Columns 2HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2
... ATLANTA, Oct. 12, 2011 CorMatrix Cardiovascular, Inc., ... delivering unique extracellular matrix (ECM) biomaterial devices that ... cardio-vascular tissue, announced today that the U.S. Food ... 510(k) clearance to market its CorMatrix® ECM® for ...
... 2011 Reportlinker.com announces that a new ... catalogue: Industrial Biotechnology ... http://www.reportlinker.com/p0655292/Industrial-Biotechnology-China-News-1109---Annual-Subscription.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Renewable_energy ... of Biotechnology Industry to be published in ...
... - Two pivotal trials initiated for treatment of iron ... - Shield Therapeutics (Shield), the independent specialty ... late-stage, mineral-derived hospital pharmaceuticals which address areas of high ... have been treated in the two Phase 3 clinical ...
Cached Biology Technology:CorMatrix Receives Carotid Artery Repair Indication for its CorMatrix® ECM® 2CorMatrix Receives Carotid Artery Repair Indication for its CorMatrix® ECM® 3Industrial Biotechnology China News 1109 - Annual Subscription 2Industrial Biotechnology China News 1109 - Annual Subscription 3Shield Therapeutics Initiates AEGIS 1 and AEGIS 2 Phase 3 Studies of ST10 2Shield Therapeutics Initiates AEGIS 1 and AEGIS 2 Phase 3 Studies of ST10 3
(Date:9/18/2014)... algal forests in the eastern Mediterranean Sea pose a ... distribution continues to expand as the climate warms, a ... of researchers led by Dr Adriana Vergs of UNSW ... for Advanced Studies in Spain, is published in the ... surveyed more than 1000 kilometres of coastline in Turkey ...
(Date:9/18/2014)... the ideal animal in which to study the genes ... into tens of thousands of freshwater streams and lakes ... adapt to the new environment. , Breeding studies between ... up one of the genes that controls tooth number, ... regulation in a freshwater population is associated with a ...
(Date:9/17/2014)... accessible and affordable health care to reproductive technologies, ... on the ability of people to identify key ... and respectfully, and find the most defensible ways ... to support these societal conversations?, The Hastings Center ... Bioethical Issues have teamed up to publish a ...
Breaking Biology News(10 mins):Tropical fish a threat to Mediterranean Sea ecosystems 2Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 2Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 3Why bioethics literacy matters 2Why bioethics literacy matters 3
... a huge portion of real estate in western North ... and fossils very different from those in adjacent terranes. ... tectonic styles, metamorphism, and volcanic origins, much like the ... new Geological Society of America Special Paper brings together ...
... Washington, DCMay 28, 2008The 2008 American Society for ... Diagnostic Immunology is presented to Steven A. Rosenberg, ... Surgery, Uniformed Services University of the Health Sciences, ... of Medicine and Health Sciences. Sponsored by Abbott ...
... for Microbiology (ASM) Merck Irving S. Sigal Memorial Award ... Genetics and Microbiology, University of Texas at Austin. Sponsored ... Memorial Award is presented in memory of Irving S. ... therapies to treat HIV/AIDS, to recognize excellence in basic ...
Cached Biology News:American Society for Microbiology honors Steven A. Rosenberg 2
... is a new-generation siRNA transfection reagent that ... 1 nM siRNA in a wide variety ... cell viability. Using low siRNA concentrations avoids ... when transfecting siRNA at higher concentrations, thereby ...
... Cell and Tissue Staining Kits are intended ... range of histological and cytological specimens. These ... antibodies manufactured by either R&D Systems or ... on the formation of the Avidin-Biotin Complex ...
... stranded RNA (dsRNA) has been shown to ... of organisms as well as insect cells ... inhibition of protein expression by utilizing sequence-specific, ... (mRNA). Attempts to induce RNA interference using ...
... jetSI-ENDO is an easy-to-use siRNA transfection reagent ... endogenous genes in a variety of cell ... with an optimized, straightforward protocol. High levels ... obtained following transfection of 20 to 100 ...
Biology Products: